Where is the field of immune biomarkers going beyond PD-L1 in the next few years?
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?
Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test?
The debate is heating up!
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Commentary on Day 3 of the European Cancer Congress in Vienna
Commentary on Day 2 of the European Cancer Congress in Vienna
Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna
What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...
What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?